MYGN
Myriad Genetics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+2/100
Last price
4.28
▼ 0.30 (6.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.58
Day high
4.83
Day low
4.22
Volume
1.80M
Market cap
$409.38M
P/E (TTM)
—
52W range
2.74 – 8.59
Trailing performance
Returnvs SPY
1W
+1.18%
-0.8%
1M
+34.17%
+33.0%
3M
-27.09%
-31.6%
6M
-9.70%
-27.9%
YTD
-30.41%
-44.7%
1Y
-46.90%
-63.3%
3Y
-73.32%
-155.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on MYGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+988.27K
Net buying
Buy transactions
13
1.00M shares
Sell transactions
1
15.00K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
3.83M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 16, 26 | SIKRI VISHAL Officer |
STOCK | 257.73K | $0 | Direct |
| Jun 11, 26 | DONNELLY BRIAN J Officer |
STOCK | 5.00K | $19.68K | Direct |
| Jun 11, 26 | RAHA SAMRAAT S. Chief Executive Officer |
STOCK | 3.54K | $13.94K | Direct |
| Jun 8, 26 | KUMAR RASHMI Director |
SELL | 15.00K | $66.84K | Direct |
| Jun 4, 26 | DAVIS MARK STEVEN Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | PHANSTIEL S LOUISE Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | DREISMANN HEINRICH Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | BISARO PAUL M. Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | SKOVRONSKY DANIEL Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | REITAN COLLEEN F. Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | NEWCOMER LEE NISLEY Director |
STOCK | 59.70K | $0 | Direct |
| Jun 4, 26 | KUMAR RASHMI Director |
STOCK | 59.70K | $0 | Direct |
| Jun 1, 26 | JAMPA RAJ Chief Technology Officer |
STOCK | 251.89K | $0 | Direct |
| May 14, 26 | BISARO PAUL M. Director |
BUY | 7.50K | $27.64K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DIAZ PAUL J |
Chief Executive Officer | 1.08M | Stock Award(Grant) |
DONNELLY BRIAN J |
Officer | 573.36K | Stock Award(Grant) |
FOX JENNIFER LYNNE |
Officer | 310.36K | Stock Award(Grant) |
MUZZEY DALE |
Officer | 329.27K | Stock Award(Grant) |
PHANSTIEL S LOUISE |
Director | 341.65K | Stock Award(Grant) |
RAHA SAMRAAT S. |
Chief Executive Officer | 1.07M | Stock Award(Grant) |
SIKRI VISHAL |
Officer | 351.22K | Stock Award(Grant) |
SOLAIMAN SHEREEN |
Officer | 267.80K | Stock Award(Grant) |
VERRATTI MARK S |
Chief Operating Officer | 632.77K | Stock Award(Grant) |
WHEELER BENJAMIN RICHARD |
Chief Financial Officer | 299.06K | Stock Award(Grant) |
Fundamentals
Market cap$409.38M
Enterprise value$504.68M
Revenue (TTM)$806.60M
Gross profit$555.20M
EBITDA$-40.30M
Net income$-112.60M
EPS (TTM)$-1.10
Free cash flow$18.19M
Total cash$115.20M
Total debt$210.50M
Book value / share$3.18
Shares outstanding95.65M
Float79.30M
Short % of float10.01%
Dividend yield0.00%
Beta (5Y)1.64
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.35
PEG ratio1.24
Price / sales—
Price / book1.35
EV / revenue0.63
EV / EBITDA-12.52
Gross margin68.83%
Operating margin-20.40%
Profit margin-13.96%
Return on equity-32.54%
Return on assets-8.60%
Debt / equity69.27
Current ratio2.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $824.50M | $837.60M | $753.20M | $678.40M | -1.6% |
| Operating revenue | $824.50M | $837.60M | $753.20M | $678.40M | -1.6% |
| Cost of revenue | $247.90M | $252.20M | $236.20M | $202.00M | -1.7% |
| Gross profit | $576.60M | $585.40M | $517.00M | $476.40M | -1.5% |
| Research & development | $106.80M | $113.40M | $88.70M | $85.40M | -5.8% |
| Selling, general & admin | $537.60M | $560.00M | $572.90M | $514.70M | -4.0% |
| Total operating expense | $644.40M | $673.40M | $661.60M | $600.10M | -4.3% |
| Operating income | -$67.80M | -$88.00M | -$144.60M | -$123.70M | +23.0% |
| Net interest income | -$8.70M | -$1.10M | -$400.00K | -$600.00K | -690.9% |
| Pre-tax income | -$395.10M | -$123.50M | -$262.20M | -$140.60M | -219.9% |
| Tax provision | -$29.20M | $3.80M | $1.10M | -$28.60M | -868.4% |
| Net income | -$365.90M | -$127.30M | -$263.30M | -$112.00M | -187.4% |
| Net income to common | -$365.90M | -$127.30M | -$263.30M | -$112.00M | -187.4% |
| Basic EPS | -3.95 | -1.41 | -3.18 | -1.39 | -180.1% |
| Diluted EPS | -3.95 | -1.41 | -3.18 | -1.39 | -180.1% |
| EBIT | -$384.60M | -$120.70M | -$259.30M | -$137.40M | -218.6% |
| EBITDA | -$330.90M | -$59.50M | -$197.40M | -$84.70M | -456.1% |
| Basic shares | 92.60M | 90.60M | 82.80M | 80.60M | +2.2% |
| Diluted shares | 92.60M | 90.60M | 82.80M | 80.60M | +2.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $149.60M | $102.40M | $132.10M | $56.90M | +46.1% |
| Cash & short-term investments | $149.60M | $102.40M | $140.90M | $114.90M | +46.1% |
| Accounts receivable | $115.30M | $121.20M | $114.30M | $101.60M | -4.9% |
| Inventory | $30.60M | $27.50M | $22.00M | $20.10M | +11.3% |
| Total current assets | $332.60M | $298.00M | $313.60M | $274.60M | +11.6% |
| Property, plant & equipment | $163.40M | $172.40M | $180.60M | $187.30M | -5.2% |
| Goodwill & intangibles | $205.00M | $548.70M | $636.90M | $666.50M | -62.6% |
| Total assets | $706.60M | $1.03B | $1.15B | $1.20B | -31.2% |
| Total current liabilities | $133.80M | $164.10M | $155.90M | $137.20M | -18.5% |
| Long-term debt | $119.90M | $39.60M | $38.50M | — | +202.8% |
| Total debt | $209.80M | $140.30M | $152.10M | $145.00M | +49.5% |
| Total liabilities | $338.60M | $326.50M | $363.30M | $312.90M | +3.7% |
| Retained earnings | -$1.12B | -$756.80M | -$629.50M | -$366.20M | -48.3% |
| Shareholder equity | $368.00M | $701.10M | $783.20M | $885.80M | -47.5% |
| Working capital | $198.80M | $133.90M | $157.70M | $137.40M | +48.5% |
| Net tangible assets | $163.00M | $152.40M | $146.30M | $219.30M | +7.0% |
| Shares issued | 93.50M | 91.30M | 89.90M | 81.20M | +2.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$365.90M | -$127.30M | -$263.30M | -$112.00M | — | -187.4% |
| Depreciation & amortisation | $53.70M | $61.20M | $61.90M | $52.70M | — | -12.3% |
| Stock-based compensation | $35.20M | $49.80M | $40.70M | $38.10M | — | -29.3% |
| Change in working capital | -$19.30M | -$54.40M | $10.70M | -$101.50M | — | +64.5% |
| Operating cash flow | $1.80M | -$8.70M | -$110.90M | -$106.30M | — | +120.7% |
| Capital expenditure | -$27.40M | -$29.70M | -$73.30M | -$45.30M | — | +7.7% |
| Investing cash flow | -$27.40M | -$11.90M | $31.90M | -$77.50M | — | -130.3% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | $64.20M | -$7.40M | $152.90M | -$8.00M | — | +967.6% |
| Free cash flow | -$25.60M | -$38.40M | -$184.20M | -$151.60M | — | +33.3% |
| End cash position | $151.30M | $111.90M | $140.90M | $66.40M | — | +35.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $190.70M | $200.40M | $209.80M | $205.70M | $213.10M | -4.8% |
| Operating revenue | $190.70M | $200.40M | $209.80M | $205.70M | $213.10M | -4.8% |
| Cost of revenue | $63.70M | $62.80M | $63.00M | $61.90M | $61.30M | +1.4% |
| Gross profit | $127.00M | $137.60M | $146.80M | $143.80M | $151.80M | -7.7% |
| Research & development | $25.00M | $27.10M | $25.50M | $28.20M | $25.60M | -7.7% |
| Selling, general & admin | $140.90M | $135.80M | $124.30M | $138.90M | $138.70M | +3.8% |
| Total operating expense | $165.90M | $162.90M | $149.80M | $167.10M | $164.30M | +1.8% |
| Operating income | -$38.90M | -$25.30M | -$3.00M | -$23.30M | -$12.50M | -53.8% |
| Net interest income | -$3.70M | -$3.40M | -$3.60M | -$3.30M | -$1.30M | -8.8% |
| Pre-tax income | -$42.60M | -$34.10M | -$8.90M | -$26.20M | -$330.60M | -24.9% |
| Tax provision | $600.00K | $0 | -$1.00M | $1.20M | -$100.00K | — |
| Net income | -$43.20M | -$34.10M | -$7.90M | -$27.40M | -$330.50M | -26.7% |
| Net income to common | -$43.20M | -$34.10M | -$7.90M | -$27.40M | -$330.50M | -26.7% |
| Basic EPS | -0.46 | -0.36 | -0.08 | -0.29 | -3.57 | -27.8% |
| Diluted EPS | -0.46 | -0.36 | -0.08 | -0.29 | -3.57 | -27.8% |
| EBIT | -$38.50M | -$30.00M | -$4.50M | -$22.40M | -$329.10M | -28.3% |
| EBITDA | -$26.00M | -$17.50M | $8.10M | -$9.80M | -$315.00M | -48.6% |
| Basic shares | 94.80M | 93.70M | 93.30M | 93.10M | 92.50M | +1.2% |
| Diluted shares | 94.80M | 93.70M | 93.30M | 93.10M | 92.50M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $115.20M | $124.40M | $149.60M | $145.40M | $74.40M | — | -7.4% |
| Cash & short-term investments | $115.20M | $124.40M | $149.60M | $145.40M | $74.40M | — | -7.4% |
| Accounts receivable | $109.50M | $123.80M | $115.30M | $118.00M | $137.00M | — | -11.6% |
| Inventory | $30.60M | $27.90M | $30.60M | $31.60M | $28.70M | — | +9.7% |
| Total current assets | $289.00M | $312.80M | $332.60M | $344.80M | $284.30M | — | -7.6% |
| Property, plant & equipment | $158.90M | $162.50M | $163.40M | $162.00M | $164.20M | — | -2.2% |
| Goodwill & intangibles | $186.10M | $192.80M | $205.00M | $214.70M | $221.10M | — | -3.5% |
| Total assets | $638.90M | $673.70M | $706.60M | $728.10M | $677.30M | — | -5.2% |
| Total current liabilities | $130.70M | $130.20M | $133.80M | $148.00M | $199.90M | — | +0.4% |
| Current debt | — | — | — | — | $59.40M | — | — |
| Long-term debt | $120.70M | $120.30M | $119.90M | $119.50M | — | $59.30M | +0.3% |
| Total debt | $210.50M | $211.50M | $209.80M | $212.30M | $154.60M | — | -0.5% |
| Total liabilities | $335.00M | $336.30M | $338.60M | $355.30M | $289.20M | — | -0.4% |
| Retained earnings | -$1.20B | -$1.16B | -$1.12B | -$1.11B | -$1.09B | — | -3.7% |
| Shareholder equity | $303.90M | $337.40M | $368.00M | $372.80M | $388.10M | — | -9.9% |
| Working capital | $158.30M | $182.60M | $198.80M | $196.80M | $84.40M | — | -13.3% |
| Net tangible assets | $117.80M | $144.60M | $163.00M | $158.10M | $167.00M | — | -18.5% |
| Shares issued | 95.60M | 94.40M | 93.50M | 93.04M | 93.10M | — | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$43.20M | -$34.10M | -$7.90M | -$27.40M | -$330.50M | -26.7% |
| Depreciation & amortisation | $12.50M | $12.50M | $12.60M | $12.60M | $14.10M | 0.0% |
| Stock-based compensation | $7.20M | $6.50M | $2.80M | $12.20M | $10.70M | +10.8% |
| Change in working capital | $13.40M | -$8.20M | -$1.60M | $21.40M | -$27.00M | +263.4% |
| Operating cash flow | -$8.30M | -$15.70M | $10.60M | $21.10M | -$13.60M | +47.1% |
| Capital expenditure | -$3.20M | -$6.50M | -$6.00M | -$6.20M | -$6.90M | +50.8% |
| Investing cash flow | -$3.20M | -$6.50M | -$6.00M | -$6.20M | -$6.90M | +50.8% |
| Financing cash flow | $2.20M | -$3.00M | -$8.20M | $56.20M | $2.60M | +173.3% |
| Free cash flow | -$11.50M | -$22.20M | $4.60M | $14.90M | -$20.50M | +48.2% |
| End cash position | $116.80M | $126.00M | $151.30M | $154.80M | $83.70M | -7.3% |
Options analytics
Put / call volume
15.00
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-76.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
3
Contracts, this expiry
Put volume
45
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.06 | -0.25 | -332.7% |
| Mar 2026 | -0.07 | -0.09 | -34.7% |
| Dec 2025 | -0.02 | 0.04 | +348.3% |
| Sep 2025 | -0.01 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.20 | 8 | $191.43M | -6.9% |
| Next quarter | -0.18 | 8 | $196.01M | -6.6% |
| Current year | -0.74 | 9 | $777.92M | -5.7% |
| Next year | -0.58 | 9 | $820.95M | +5.5% |
Analyst targets & ownership
Mean target$3.91
High target$8.00
Low target$2.00
Implied upside-8.59%
Analyst count8
ConsensusHOLD
Strong buy / Buy0 / 1
Hold5
Sell / Strong sell1 / 2
Held by insiders4.01%
Held by institutions97.09%
Institutions holding277
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.26
+0.56% from price
SMA 20
4.01
+6.84% from price
SMA 50
3.62
+18.33% from price
SMA 100
4.29
-0.13% from price
SMA 200
4.72
-9.40% from price
EMA 12
4.20
+1.83% from price
EMA 26
3.99
+7.29% from price
EMA 50
3.99
+7.33% from price
RSI (14)
58.2
Neutral
MACD (12,26,9)
0.21
Hist 0.05
ATR (14)
0.29
6.86% of price
Realised vol 30D
62.4%
Annualised
Bollinger upper
4.71
20, 2σ
Bollinger lower
3.30
20, 2σ
50 / 200 cross
Death
3.62 vs 4.72
Trend bias
Below 200
-9.40%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.10
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
62.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-65.0%
Peak to trough
Max drawdown 5Y
-91.2%
Peak to trough
ATR 14
0.29
6.86% of price
Beta (reported)
1.64
5Y monthly, from filing
Short interest
Shares short
9.35M
Prior 7.68M
Change vs prior
+21.6%
Shorts adding
% of float
10.01%
Elevated
% of shares out
9.77%
Against total outstanding
Days to cover
5.0
Liquid
Float
79.30M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Sep 9, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Sep 1, 26 | Piper Sandler | DOWNGRADE | Overweight | Underweight |
| Aug 18, 26 | Stephens & Co. | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 3, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 31, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| May 6, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| May 6, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Feb 24, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Feb 24, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Nov 11, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Nov 5, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateMar 26, 2009
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Periodic Financial Reports
10-Q · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-23
Offering Registrations
S-8 · 2026-06-04
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-05
Proxy Statements
DEF 14A · 2026-04-14
Headlines
Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets
Simply Wall St. · 3d ago
Why Is Myriad Genetics (MYGN) Stock Soaring Today
StockStory · 4d ago
1 Volatile Stock on Our Buy List and 2 We Question
StockStory · 5d ago
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
StockStory · 13d ago
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
MarketBeat · 16d ago
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
Simply Wall St. · 19d ago
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
StockStory · 20d ago
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
GlobeNewswire · 21d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.